Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab.
Rodrigo BorregaCarlos AraújoNádia AguiamFernando MagroJoão Eurico FonsecaSilvio DaneseJoão Almeida LopesJoao GoncalvesPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
Future studies that evaluate the patient-, product-, and disease-related factors behind the immunogenicity of adalimumab are required because the evidence published so far does not completely explain the temporal increase in immunogenicity rates detected in this analysis.